| Autor: |
Vita, Emanuele, Stefani, Alessio, Piro, Geny, Mastrantoni, Luca, Cintoni, Marco, Cicchetti, Giuseppe, Sparagna, Ileana, Monaca, Federico, Horn, Guido, Russo, Jacopo, Barone, Diletta, Di Salvatore, Mariantonietta, Trisolini, Rocco, Lococo, Filippo, Mazzarella, Ciro, Cancellieri, Alessandra, Carbone, Carmine, Larici, Anna Rita, Mele, Maria Cristina, Pilotto, Sara |
| Předmět: |
|
| Zdroj: |
Cancer Immunology, Immunotherapy; Nov2023, Vol. 72 Issue 11, p3803-3812, 10p |
| Abstrakt: |
Background: Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness to IT in obese patients; however, their prognostic role in SCLC is currently controversial. Methods: Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting for measuring glycemia, insulin, ghrelin, leptin and adipokines (TNF-α, IFN-γ, IL-6 and MCP-1). Patients with known history of DM type II or metabolic syndrome with HOMA index > 2.5 were considered insulin resistant (IR). Results: In ES-SCLC pts receiving maintenance IT, increased leptin concentration and higher leptin/visceral adipose tissue (VAT) ratio were significantly associated with prolonged PFS. By applying a hierarchical clustering algorithm, we identified a cluster of patients characterized by higher leptin values and lower pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) who experienced longer PFS (13.2 vs 8.05 months; HR: 0.42 [0.18–0.93] p = 0.02) and OS (18.04 vs 12.09 mo; HR: 0.53 [0.25–1.29] p = 0.07). Conclusions: Adipokines can play a crucial role to determining effectiveness of anti-cancer immunotherapy. The role of metabolic immune dysfunctions needs further pre-clinical validation and is currently investigated in the larger prospective cohort. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink